Inclusion Criteria:
- ALL de novo high-risk criteria
- Age 15-55 years (55-60 years patients will be included at the discretion of the
medical team that will attend)
- No prior treatment, except Emergency leukapheresis Emergency treatment of
hyperleukocytosis with hydroxyurea Urgent cranial irradiation (one dose) for CNS
leukostasis Mediastinal irradiation for urgent superior vena cava syndrome
- General condition suitable scale (ECOG 0-2), or> 2 if due to ALL
- Negative pregnancy test for women of childbearing age
- Written informed consent because, although the protocol does not include the use of
investigational drugs, biological samples sent there for them
Exclusion Criteria:
- L3 type ALL or mature phenotype B (sIg +) or cytogenetic abnormalities characteristic
of mature B-ALL (t (8; 14), t (2, 8), t (8; 22)). For these patients is available
BURKIMAB protocol.
- LAL Ph (BCR-ABL) positive. For these patients have the protocol ALL-Ph-08 (if under
55) or LALOPh (if over 55).
- Lymphoid blast crisis of chronic myeloid leukemia
- Biphenotypic acute leukemia or bilinear according to the criteria of EGIL group
- Undifferentiated acute leukemias
- Patients with a history of coronary artery disease, valvular or hypertensive heart
disease, contraindicating the use of anthracyclines
- Patients with chronic phase of activity
- Patients with severe chronic respiratory failure
- Kidney failure due to ALL
- Serious neurological disorder not due to the LAL
- History of pancreatitis
- Pregnancy or breastfeeding
- Mental or psychiatric illness preventing informed consent is given for sending
samples or properly follow the study
- General condition affected, not attributable to the ALL